J.S. Wolinsky, MD, G. Comi, MD, M. Filippi, MD, D. Ladkani, S. Kadosh and G. Shifroni The European/Canadian Glatiramer Acetate Study Group
University of Texas Health Science Center at Houston (Dr. Wolinsky); the Clinical Trials Unit (Dr. Comi) and the Neuroimaging Research Unit (Dr. Filippi), Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy; and Teva Pharmaceuticals, Ltd. (D. Ladkani, S. Kadosh, and G. Shifroni), Kiryat Nordau, Netanya, Israel.
All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months.
There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate.
Over the entire study the accumulated T2 disease burden was 34.2% less
for those always on glatiramer acetate.
© 2002 American Academy of Neurology